Corporate News

Hengsai Biological DC Vaccine for EBV-related Hematological Tumors Project Landed in Ruijin Hospital of Lecheng, Hainan Province
January 5, 2026 115
On December 30, 2025, Hengsai Bio's premiere pipeline KSD-101 dendritic cell (DC) vaccine for the treatment of EBV-related hematological tumors, a project of translational application of new biomedical technologies, was officially landed in the Hainan Hospital of Ruijin Hospital, Affiliated to the Medical College of Shanghai Jiao Tong University. The project has been declared and selected, evaluated by experts, verified at the production site and approved by the Health Commission of Hainan Province, the Administration of Lecheng Advance Zone and the Drug Administration jointly. ...
View details
Hengsai Biologicals Closes First Round of Strategic Financing
December 31, 2025 106
Recently, Hengsai Biologics completed the first round of strategic financing, exclusively invested by Tianshili Capital. This round of funding will be mainly used to promote the R&D and clinical trials of the core pipeline as well as the company's internationalization strategy layout. Both parties have carried out extensive and in-depth communication and planning on domestic and international project cooperation. In the future, they will give full play to their respective business advantages, with equity investment as the core link, through business synergy,...
View details
authorized access to international regulations and policies
December 30, 2025 121
1. PURPOSE This document describes KOUSAI´s position, and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. This document describes KOUSAI´s position and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. SCOPE We cover ...
View details
Kousai Bio KSD-101 Receives U.S. FDA Fast Track Designation (FTD)
December 26, 2025 141
On December 25, 2025, Hengsai Bio, an innovative Chinese biopharmaceutical company, announced a significant news - its original dendritic cell vaccine (DC vaccine), KSD-101 injection, independently developed by Hengsai Bio, has been formally granted Fast Track Designation, FTD, by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) EBV-positive gonorrhea. Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) EBV-positive lymphoma...
View details
Kousai Bio DC Vaccine for Pancreatic Cancer Program Officially Launched
October 21, 2025 338
On October 21st, 2025, the Cancer Hospital of Fudan University held a kick-off meeting for the project "KSD-301 in combination with AG regimen (Gemcitabine, Albumin Paclitaxel) for the treatment of locally advanced unresectable pancreatic cancer". The project is led by Prof. Xianjun Yu, President of the Affiliated Cancer Hospital of Fudan University and Director of the Institute of Pancreatic Tumor Research of Shanghai and Fudan University, as the principal investigator, and the investigational drug KSD-301 is Hengsai's...
View details
Kousai Bio DC Vaccine Project Landed in Lecheng Pioneer Zone
September 1, 2025 599
On the morning of August 30, 2025, the Policy Promotion Meeting for New Biomedical Technologies in LeCheng Advanced Zone and the First Batch of Enterprises Concentrated Signing Conference were held in Boao LeCheng Never Ending International Innovative Pharmaceuticals and Devices Exhibition. Hainan Provincial People's Government, Hainan Provincial Department of Industry and Information Technology, Hainan Provincial Healthcare Commission, Hainan Provincial Medical Insurance Bureau, Hainan Provincial Drug Administration, Hainan International Economic and Development Bureau, Lecheng Advanced Zone Administration, Qionghai Municipal People's Government, Lecheng...
View details
Hengchuang Frontier・Sai Leads Health | Grand Opening Ceremony of Hengsai Bio-Linkport R&D and Production Base
August 15, 2025 585
On August 15, 2025, the opening ceremony of the R&D and production base of Hengsai Biologicals in Lingang was held grandly in the 10th phase of Life Blue Bay Intelligence Park in Lingang New Area. With the theme of "Hengchuang Frontier, Sai Leads Health", the ceremony invited the Lingang Administrative Committee, industry experts, shareholders' representatives, partners, leaders of the park and all the staff of Hengsai Biologicals to witness this important moment together. Har...
View details
2025 EHA: Kousai Bio’s KSD‑101 DC vaccine unveils breakthrough data, expanding new frontiers in EBV hematologic tumor therapy
June 17, 2025 744
Hengsai BioItaly - Milan The 30th Annual Meeting of the European Hematology Association (EHA 2025) was successfully concluded from June 12 to 15 in Milan, Italy. As a global top event in the field of hematology, EHA gathered the world's top experts, scholars and industrial pioneers to discuss the latest breakthroughs and future direction of blood disease diagnosis and treatment. In this international academic feast, Hengsai Biotechnology, as one of the...
View details
2025 Annual Meeting and Spring Reunion Special Hengsai Biology
April 25, 2025 895
The snake offered a new chapter, and the elites went to the spring banquet together. At the time when the snake is coiled up and everything is new, all the staff of Hengsai Bio-technology gathered together and held the 2025 Annual Meeting and Annual Summarization Activity in Zhoushan, Zhejiang Province. The team of Hengsai traveled on the waves, refined tacit understanding with collaboration, and cohesion of consensus with laughter, and drew the prelude of the New Year together among the blue sea and golden sand. Breaking through ten thousand hectares of waves, the team went on a journey to the blue sea...
View details
Hengsai Bio DC Vaccine for Kidney Cancer Program Officially Launched
March 4, 2025 881
On March 3, 2025, Hengsai Bio's self-developed KSD-201 DC vaccine for advanced renal cell carcinoma was officially launched at Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology ("Wuhan Tongji Hospital").
View details

Expand more!